Top Markets
Coin of the day
Entropy Neurodynamics Limited Entropy Neurodynamics Limited

Entropy Neurodynamics Limited

ENP
주식 순위 #26484
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical... Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
주가
$0.02468497
마지막 동기화: 2026-07-30
시가총액
$40.28M
변동 (1일)
0.00%
변동 (1년)
-
국가
AU
거래 Entropy Neurodynamics Limited (ENP)

카테고리

Entropy Neurodynamics Limited (ENP)의 주식 분할 이력
Entropy Neurodynamics Limited 주식 (심볼: ENP)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 20, 2026에 발생했습니다.
Aug 20, 2026 이전에 매수한 ENP 주식 1주는 현재 0주의 ENP 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH